Article: TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma.

Article: NeoPharm Announces New Data On Novel Tumor-Targeting Agent in Terminal Brain Cancer.
Business Wire;  November 19, 2001 ;     700+ words ......in recurrent malignant glioma, which is diagnosed...San Francisco. Malignant glioma, which includes...diagnosed with malignant glioma usually live...treatment for malignant glioma. Additional...in targeting malignant glioma, we're encouraged...has shown ...

Article: TransMolecular Presents Imaging and Pharmacokinetic Analysis of (131)Iodine-TM601 at Society for Nuclear Medicine Meeting.
Business Wire;  June 17, 2008 ;     700+ words ......patients with primary malignant glioma or solid tumor metastases...trials in melanoma and malignant glioma with radiolabeled TM601...unlabeled version of TM601 in malignant glioma. Six patients received...receptors expressed on tumor cells, but not on normal, ...

Article: Dosing Initiated in TransMolecular's Phase 1/2 Clinical Trial for Intravenous Administration of (131)Iodine-TM601 in Patients with Recurrent Malignant Glioma.
Business Wire;  September 29, 2008 ;     700+ words ......patients with recurrent malignant glioma. The trial will focus on...specifically targets and binds to tumor tissue. There is a great...patients with recurrent malignant glioma, one of the most serious...to receptors expressed on tumor cells, but not on normal, ...

Article: TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma.
Business Wire;  December 22, 2008 ;     700+ words ......designation for 131I-TM601 in malignant glioma, as well as for the non-radiolabel...TM601 for the treatment of malignant glioma. The receipt of our third...receptors expressed on tumor cells, but not on normal, healthy...rapidly taken up into these tumor cells, ...

Article: NeoPharm To Announce IL13-PE38 Phase I/II Data for Malignant Glioma At Society for Neuro-Oncology - SNO - Meeting Tomorrow.
Business Wire;  November 15, 2001 ;     595 words ......findings which suggest that the Company's novel tumor-targeting agent may have potential as a treatment for malignant glioma, a terminal brain cancer for which there...new therapeutic options for patients with malignant glioma. Malignant glioma, which includes glioblastoma ...

Article: EOPHARM BEGINS NEW GLOBAL TRIAL OF IL13-PE38 FOR MALIGNANT GLIOMA.
Worldwide Biotech;  October 1, 2002 ;     626 words ......IL13-PE38, NeoPharm's novel tumor-targeted agent. Enrollment...recurrent or progressive malignant glioma. The trial is being conducted...effective treatment for malignant glioma has influenced our clinical...The Mechanism of IL13-PE38 Malignant glioma cells, as compared to ...

Article: TransMolecular Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma.
Business Wire;  January 7, 2008 ;     700+ words ......the treatment of malignant glioma. The company had...trial in multiple tumor types. We are...status for TM601 in malignant glioma, stated Michael...drug candidate in malignant glioma. This designation...FDA approval for malignant glioma, this designation...the ...

Article: Techniclone Expands Solid Tumor Brain Cancer Study to Include UCLA.
Business Wire;  June 21, 1999 ;     700+ words ......its ongoing Phase II trial for the treatment of malignant glioma (solid tumor brain cancer). This trial was started at the...cells account for up to 50% of the mass of a tumor and are found primarily at the tumor core. Once concentrated in necrotic regions throughout...the drug is able to ...

Article: TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting.
Business Wire;  April 14, 2008 ;     700+ words ......Phase 2 studies in malignant glioma and melanoma are...trial for recurrent malignant glioma. Using the complex...non-radiolabeled TM601 in malignant glioma. We believe its...receptors expressed on tumor cells but not on normal...radiation, killing the tumor cell ...

Article: NeoPharm Investigators Present Preliminary Phase I Data of Cintredekin Besudotox in the Treatment of Malignant Glioma at Initial Diagnosis.
Business Wire;  October 10, 2005 ;     700+ words ......newly diagnosed malignant glioma patients at...newly-diagnosed malignant glioma. The secondary...patients with malignant glioma. The study...treatment of malignant glioma from initial...newly-diagnosed malignant glioma undergo a gross...with recurrent ...

Article: Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine.
Alternative Medicine Review;  October 1, 2000 ;     216 words ......elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and...of high hydrostatic pressure (P) to tumor cells in the presence of a slow-reacting membrane-impermeab...immunogenic potential of PCL-modified tumor cells both in vitro and in vivo. ...

Article: Aphton Reports Activity of IGN101 in Reducing Disseminating Tumor Cells From Patients With Epithelial Cancers.
Business Wire;  May 16, 2005 ;     700+ words ......ability of IGN101 to decrease circulating tumor cells in peripheral blood. Elevation of circulating tumor cells has been shown to predict short survival...29 and 57. Analyses of circulating tumor cells in peripheral blood were performed on...

Article: NEOPHARM Announces Presentation of Final Safety Data from Phase 1 Trial of CINTREDEKIN BESUDOTOX for Newly Diagnosed Malignant Glioma.
Business Wire;  November 20, 2006 ;     700+ words ......patients with newly diagnosed malignant glioma. This safety data is very encouraging...treatment option for patients with malignant glioma at initial diagnosis, said Michael...patients with newly diagnosed malignant glioma following tumor resection. CED...patients with ...

Article: NEOPHARM GETS ORPHAN DRUG STATUS FOR IL13-PE38.
Biotech Business;  January 1, 2002 ;     496 words ......announced that its novel tumor-targeting agent - IL13- PE38...Administration for the treatment of malignant glioma, a terminal brain cancer...assistance from the FDA. Malignant glioma, which includes glioblastoma...each year. Most people with malignant glioma usually live for ...